Fig. 3From: Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort studyRelative hazard of ILD-related hospitalization using the most sensitive ILD definition. ABA abatacept, COPD chronic obstructive pulmonary disease, hosp hospitalization, ILD interstitial lung disease, MTX methotrexate, RTX rituximab, TCZ tocilizumabBack to article page